Results for
"[search-keyword]"
Sponsor content
179 result(s) found, displaying 11 to 20
-
Prescription medicine registrationActive ingredients: Brentuximab vedotin.
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 4 TAKEDA, guanfacine (as hydrochloride) 4 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIVTENCITY maribavir 200 mg film coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 30 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ICLUSIG ponatinib (as hydrochloride) 10 mg film-coated tablet bottle.
-
Australian Public Assessment Report (AusPAR)AusPAR for Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies